Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced that both randomised controlled trials in the EASE phase III programme, investigating the use of empagliflozin in combination with insulin therapy in adults with type 1 diabetes, met their primary endpoint. As quoted in the press release: Type 1 diabetes currently affects approximately 30 million … Continued